Cystic changes of the thyroid remain a diagnostic dilemma with regard to malignancy due to insufficient information gained by fine needle aspiration, sonography and routine nuclear medicine procedures. As complementary soluble parameters we measured neopterin and thyroglobin levels in cyst fluids and in serum of 81 patients with disorders of the thyroid. Based on clinical, cytological and histological information, patients were divided into five groups. (I): Serous cysts (n=41), (II): hemorrhagic cysts (N=18), (III): cysts ' with evidence for inflammation clinically or by histology (n= 11), (IV): malignancy in cysts by histology (n = 6), (V): cysts containing "honey" like, brownish fluid of high viscosity (n = 5). Neopterin concentration in cyst fluids vs. serum in group (I) were not different, 8.8± 4.3 nmol/l in vs. 6.67± 3.34 nmol/l. In groups II-V neopterin concentration in cysts were higher than in serum, (II): 21.1 ± 18.7 nmol/l vs. 5.6± 2.56 nmol/l, (III): 30.6± 24.9 nmol/l vs. 6.1 ± 2.9 nmol/l, in (IV): 35± 23.5 vs. 10.98± 7.0 nmol/l and (V): 36.0± 23.9 vs. 5.9± 3.32 nmol/l respectively. In patients with proven benign histology at surgery, neopterin levels in cystic fluid were significantly lower than in cysts harbouring malignancy, 8.5±4.6 vs. 35.4±23.5 (Z=3,17, p=O. 0015). There were no significant differences between groups II, III IV and V regarding neopterin concentrations in cysts. Elevated serum neopterin levels were observed in 2/6 patients with aggressive thyroid cancer (group IV). However, average neopterin concentrations in serum of patients of group IV were not higher than in 15 patients from group I with benign histology (P=O.l). Significantly lower levels of thyroglobin in cyst fluid were found in group V ("honey" cysts) in comparison to all other groups pooled, 2.67± 1.82 f..lg/rnl vs. 6.76± 3.97 f..lg/ml, (Z=2.l5, p=0.031), four of five cysts in group V resolved after fine needle aspiration. We found no correlation between thyroglobin levels in cyst fluid and in serum.
Introduction
The thyroid gland is a target for various autoim-
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Pteridines / Vol. 4 / No. 4 mune processes, most prominent are Grave's disease and autoimmune Hashimoto thyroiditis (HT). To some extent the immune system may also play a role in thyroid malignancy as survival decreases with age (l). The role of HT and its association to malignant lymphoma of the thyroid was discussed, the association of HT with thyroid cancer is still unclear (2) (3) (4) . Lymphocytic infiltration is also observed in papillary carcinoma, its relation to' prognosis, however remains controversial (5) .
Cystic changes are another form of thyroid pathology mostly arising from nodular transformation of goiters. Median neck cysts, (thyroglossal cyst) may be lined by stratified squamous epithelium or by cells which are resembling thyroidal acinar epitheliu, however such cysts have no connection to thyroid parenchyma and are rare (6) . Parathyroid cysts characteristically containing clear watery fluid and a high concentration of parathyroid hormone, are occasionally reported (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
In the thyroid gland, benign cystic degeneration may occur in colloid nodules due to the imbalanced secretion and absorption of colloid. This disturbed resorption is most prominent in the center of the nodule that is aggravated by additional local oedema leading eventually to cyst formation. Hemorrhage, in an adenom in the first stage, causes disruption of the follicular structure, in a later stage liquification takes place by the action of phagocytic Mfoamy" cells that remove cell elements and debris ~o that a pseudocyst will remain. Histologically one may find organisation of cyst wall by fibrosis, atrophic changes or lymphocytic inftltration (17, 18) . Cysts can also occur as degeneration in neoplastic lesions, when the tumor outgrows its blood supply (19) .
Between 1O~25% of scintigraphically cold nodules show cystic degeneration (7, 20) . Association of primary thyroid cancer with solitary cold nodules varies between 5~25% in different reports (21) (22) (23) . Cystic lesions of the thyroid are generally not interpreted as unfavourable findings unlikely to be associated with cancer, the reported incidence of malignancy being very low, up to 2.9% (17, (24) (25) (26) (27) (28) (29) . Alerting results, however were reported from clinically preselected patients harbouring" cold nodules" and cystic degeneration, who at surgery had a high incidence of thyroid cancer within cystic lesions ranging from l3-34% (19, 30, 31) The underlying pathology of cystic degeneration within the thyroid is difficult to assess sometimes. Sonography offers valuable structural information, fine needle biopsy can usually provide information concerning malignant changes in thyroid nodules (17, 20) . This may be unfortunately not true in thyroid cysts, due to paucity of representative material gained by aspiration. Even when applying special techniques for biopsy of the cyst's wall (32), a precise diagnosis remains difficult because of the localisation of malignant lesions in a small area of the wall (33) .
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Thyroid scintigraphy with Technetium-99m or Iodine are less valuabel: They show only a "cold nodule" (17) and differential diagnosis of changes occurring simultaneously with cystic degeneration of the thyroid cannot be estimated. Applying double tracer techniques e.g. Thallium-20lrmrc or 99mTc-sestamibirmrc, may supply additional functional information somtirnes. Testing soluble components in thyroid cyst fluid might provide additional evidence for malignancy to facilitate selection of cases for surgery. The aim of this study was therefore to investigate soluble parameters measured in cyst fluid and to correlate the result with clinical information, cytology and to post operative histological findings. We chose to measure Neopterin as a marker of immune activation. Neopterin is a metabolite of guanosine triphosphate, large amounts of which are produced by macrophages upon stimulation with interferon gamma from activated T-Iymphocytes (34).
Patients and Methods
Eighty one patients with various cystic lesions accompanied with diffuse or multinodular goiters grade I-III (WHO classification) were studied, when they came to the outpatient thyroid unit during the years 1992 -1993. Samples of more than one ml cyst fluids were drawn by fine needle aspiration. All patients underwent clinical evaluation, 99mTc scintigraphy and sonography of the thyroid (7 MHz linear scanner). Patients were divided into five groups. Cystic thyroid aspirates were drawn into 20m 1 syringes using 22-19 Gauge canulas. Fluid was immediately evacuated into EDTA containing monovets, centrifuged for 5 min at 1500 g, the supernatant was separated and stored at-20 c e. Cytological evaluation of cytoprecipitate or blank smear of cystic content was done routinely after PAP staining. Histology of the thyroid was evaluated in part of the cases at thyroidectomy.
Neoplerin detennination
Serum levels were measured using radioimmu- noassay (lMMU-test. Henning-Berlin, Germany) according to the instructions of manufacturer. In cyst fluid alkaline supernatants were neutralised to a final pH of 7.15-7.4 with an equal volume of phosphate buffered saline (lOOmM, pH-7.0) and measured in supernatant after thorough mixing and spinning at 8000g for 2 min. In a selected number of samples, neopterin levels in cystic fluid were validated using HPLC as a golden standard (35), a good correlation (r, =0.99, p<O.OOl, data not shown) was found.
Thyroglobin
Thyroglobin (TG) levels in serum were measured with radioimmunoassay kit (DYNOtest, Henning Berlin, Germany). For measuring of TG in Thyroid cysts a further 1: 10 dilution was performed.
Statistical analysis
Statistical analysis was done using Wilcoxon test for differences between groups. Wilcoxon paired rank test was applied when comparing serum and cyst concentration of the same patients, Spearmann's rank test for correlations between different parameters.
Results
Group I : Patients with serous cysts (n=41)which were mostly large, showed low neopterin levels m cystic fluid, being only slightly higher than those measured in serum; 8.8± 4.3 nmol/l in cysts vs. 6.67 ± 3.34 nmol/l in serum, (Table 1, of foamy cells and sideroblasts, and to a lesser extent inflammatory cells. Serum neopterin levels were normal (~ 8.7, 5.6± 2.56 nmol/l) and were significantly lower tha n concentrations in cysts (P<0.OOO2). Three patients underwent thyroidectomy with benign histology.
Group Ill : Ten patients with either clinical, cytological or histological evidence for inflammation, they had significantly increased neopterin levels in cystic fluid (30.6± 24.9 nmol/l), while normal in serum 6.1 ± 2.9 nmol/l, (P = O.OI); 3/11 were operated and had benign histology. Group IV: included 6 patients with adenomas or malignant transfonnation of the thyroid, one case of known anaplastic carcinoma with a necrotic tumor mass showed significantly elevated neopterin levels hoth in serum 20 nmolll as well as in supernatant of cell debris (80 nmolll). In this group average levels of neopterin showed a marked elevation in cysts 35± 23.5 nmolll vs. 1O.98± 7.0 nmolll in serum (p= 0.0047). Neopterin levels in cyst fluid were significantly higher than in 15 cysts of patient in group I with benign postoperative histolotgy; average 35.4± 23.5 vs. 8.5± 4.6 nmol/I (Z=3.17, P=0.OOI5). Group V: included 5 patients with "honey" cysts either related to adenoma or to small cysts. These cysts showed on average high levels of neopterin (36± 23.9nmolll) but serum levels were normal (5.9± 3.3 nmol/l), p=0.0047. In 4 patients after fine needle aspiration the cyst resolved and in one improved significantly. The findings are also summarised in Fig. I and Fig. 2 . Concerning TG levels in cystic f1uid (see also Fig. 3 ), we found no difference between the groups I-IV. Significantly lower levels of TG in cystic fluid were found in group V (harbouring "honey" cysts) when compared to all other graus pooled 2.67± l.82 flg/ml vs. 6.76± 3.97 flg/ml. (Z=2.IS, p=O.o31). No correlation was found between levels of TG in serum and in the cystic f1uid. in none of the groups alone or pooled.
Discussion
Neopterin is a sensitive marker of cellular immune system activation that is release by macrophages upon stimulation by interferon gamma. It is found to be increased during various pathologies including acute infections, autoimmune diseases, sarcoidosis. intlammatory bowel diseases, allograft rejection and malignancies (36, 37) . For diagnostic purposes neopterin concentrations are usually detennined in body tluids like serum or urine. However. elevated neopterin values in serum can be found in many systemic diseases that involve cell-mediated immune response including malignant neoplasia, as mentioned above. Therefore elevated neopterin concentrations are by no means specific for malignant diseases.
In thyroid cysts, pathological changes occur on a local level. This is also reflected by our data, by neopterin levels in serum remaining within the normal range in the non neoplastic groups (I-III and Group V) and always below the values measured in cysts. Thus increase of neopterin concentrations in cysts indicates local production due to local immune response. Only in patients with neoplastic thyroid disease an elevation of serum neopterin was observed. which corresponds to data presented previously (38) and indicates that in these patients a more intense exchange of locally produced neopterin takes place. From our own experience, in patients with thyroid malignancy, increased serum neopterin levels are frequently observed (unpublished data).
In patients with elevated neopterin levels in cystic fluid with no malignancy, local lymphocytic infiltration or phagocytic activity was found. This is true also for patients with hemorrhage of the thyroid, where tissue damage and subsequent repair mechanisms involving inflammatory reaction may explain the observed elevation of neopterin. Our preliminary observation shows persistent elevation of neopterin also in older hemorrhage as judged from the colour of the fluid. Whether blood degradation products including iron may playa role in this phenomenon is still unclear. Our data suggest moreover, that low levels of neopterin in cystic fluid have a high negative predictive value with regard to malignancy within the "cyst" structure. None of the 15 patients in group I, showing nonnal levels of neopterin in cystic fluid had cancer by histology. On the other hand significant elevation of neopterin levels in th e cystic fluid may be associated with malignancy, especially when elevation of serum levels are detected too, provided that other diseases are excluded. Certainly our preliminary observation still have to be proven in a larger series. Combining neopterin data with further soluble parameters in cystic fluid may allow better judgment of underlying pathology. Our findings suggest that neopterin measurements in thyroid cyst when u sed in a clinical setting as an additional parameter in evaluating these lesions may provide further valuable infonnation to establish an appropriate startegy of treatment.
